Unbiased AI-powered news
Federal agencies have held 20 meetings with industry groups this year on updates to the No Surprises Act's Independent Dispute Resolution process. Health care providers and their trade groups accounted for 13 meetings while insurers had four. The final rule, first proposed in November 2023, is expected any day.
medpagetoday.comThe federal government is supposed to unveil changes to the No Surprises Act’s arbitration process any day now, as of May 11, 2026. Health care providers and insurers are racing to have the final word before the new No Surprises Act arbitration rules are published.
The four agencies crafting the Independent Dispute Resolution Operations final rule held 20 meetings with industry groups so far this year as of May 11, 2026.
Just four of the 20 meetings were with health insurers or their trade groups. Thirteen of the 20 meetings were with providers or their trade groups, and three of the 20 meetings were with other sectors. Stakeholders can request to meet with agency officials to highlight their priorities and submit relevant materials.
@statnews reported that the meetings were mostly virtual. The departments of Health and Human Services, Labor, Treasury, and the Office of Personnel Management released an initial version of the Independent Dispute Resolution rule in November 2023. The proposed changes to the No Surprises Act arbitration process include tweaks to how claims can be grouped together.
The proposed changes to the No Surprises Act arbitration process include more transparency into pre-arbitration negotiations and changes to fees. The law has protected patients, but its costs are soaring as far more disputes are funneled through arbitration. Doctors and insurers are battling to reshape the controversial No Surprises Act arbitration process, which has long frustrated both sides.
Tara Bannow, hospitals and insurance reporter for @statnews, wrote that one side is getting a lot more face time with officials. The final rule has been a long time coming. Providers have used the stakeholder meeting process far more actively than insurers in the months leading up to the expected release.
Single source — no framing comparison available.
upi.comThe Food and Drug Administration approved enlicitide, sold as Lipfendra, on Thursday. Manufactured by Merck, the pill inhibits PCSK9 and cut LDL levels by up to 60 percent in a 24-week trial of 2,912 participants. It carries a list price of $315 for a 30-day supply and will reach…
washingtonpost.comFlooding along the Guadalupe River has killed at least one person in central Texas. The same area recorded more than 130 deaths in flash floods last summer. Governor Greg Abbott confirmed the fatality in a Thursday update.
dailywire.comKalshi will allow bets on selected clinical trial results and full FDA decisions, starting with Phase 3 studies from established companies. The FDA separately approved Merck's Lipfendra cholesterol pill based on studies showing up to 60% LDL reduction.